TWI732773B - 用於奈米顆粒冷凍乾燥形式的組成物及方法 - Google Patents

用於奈米顆粒冷凍乾燥形式的組成物及方法 Download PDF

Info

Publication number
TWI732773B
TWI732773B TW105123227A TW105123227A TWI732773B TW I732773 B TWI732773 B TW I732773B TW 105123227 A TW105123227 A TW 105123227A TW 105123227 A TW105123227 A TW 105123227A TW I732773 B TWI732773 B TW I732773B
Authority
TW
Taiwan
Prior art keywords
compound
cyclodextrin
composition
hydroxyalkyl
freeze
Prior art date
Application number
TW105123227A
Other languages
English (en)
Chinese (zh)
Other versions
TW201717914A (zh
Inventor
羅傑 雅達米
裕偉 王
海青 尹
立平 王
棟 劉
文彬 應
Original Assignee
日商日東電工股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日東電工股份有限公司 filed Critical 日商日東電工股份有限公司
Publication of TW201717914A publication Critical patent/TW201717914A/zh
Application granted granted Critical
Publication of TWI732773B publication Critical patent/TWI732773B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105123227A 2015-07-22 2016-07-22 用於奈米顆粒冷凍乾燥形式的組成物及方法 TWI732773B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
US62/195,356 2015-07-22

Publications (2)

Publication Number Publication Date
TW201717914A TW201717914A (zh) 2017-06-01
TWI732773B true TWI732773B (zh) 2021-07-11

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105123227A TWI732773B (zh) 2015-07-22 2016-07-22 用於奈米顆粒冷凍乾燥形式的組成物及方法

Country Status (23)

Country Link
US (3) US10300018B2 (https=)
EP (1) EP3324932B1 (https=)
JP (2) JP6875373B2 (https=)
KR (1) KR102716928B1 (https=)
CN (2) CN108024957B (https=)
AU (1) AU2016297153B2 (https=)
CA (1) CA2992849C (https=)
CY (1) CY1123984T1 (https=)
DK (1) DK3324932T3 (https=)
EA (1) EA035761B1 (https=)
ES (1) ES2862191T3 (https=)
HR (1) HRP20210523T1 (https=)
HU (1) HUE053990T2 (https=)
IL (2) IL288342B2 (https=)
LT (1) LT3324932T (https=)
MX (1) MX373982B (https=)
PL (1) PL3324932T3 (https=)
PT (1) PT3324932T (https=)
RS (1) RS61607B1 (https=)
SI (1) SI3324932T1 (https=)
SM (1) SMT202100196T1 (https=)
TW (1) TWI732773B (https=)
WO (1) WO2017015552A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100196T1 (it) * 2015-07-22 2021-05-07 Nitto Denko Corp Composizioni e metodi per forme liofile di nanoparticelle
IL275334B2 (en) 2017-12-12 2026-04-01 Lead Biotherapeutics Ltd Solid lipid nanoparticles for intracellular release of active ingredients and method for their production
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
CN112789031B (zh) 2018-09-28 2023-03-24 胡桃钳医疗公司 用于核酸递送的包含脂化的阳离子肽化合物的脂质纳米颗粒制剂
EP4365289A3 (en) * 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
WO2021060440A1 (ja) * 2019-09-26 2021-04-01 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
WO2021174149A2 (en) * 2020-02-28 2021-09-02 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
EP4138791A1 (en) * 2020-04-20 2023-03-01 Board of Regents, The University of Texas System Biologically active dry powder compositions and method of their manufacture and use
US12178921B2 (en) * 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
JPWO2022071582A1 (https=) 2020-10-02 2022-04-07
WO2023064891A1 (en) 2021-10-14 2023-04-20 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
AU2024296743A1 (en) * 2023-07-13 2026-02-26 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN103748078A (zh) * 2011-06-08 2014-04-23 夏尔人类遗传性治疗公司 可裂解脂质

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
BRPI0314042B8 (pt) * 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
PT1633327E (pt) * 2003-06-04 2010-11-08 Univ Georgetown Método para melhoramento da estabilidade e duração de armazenamento de complexos lipossomais
AU2005302255A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
EP1811960A2 (en) 2004-11-19 2007-08-01 Novosom AG Improvements in or relating to pharmaceutical compositions for local administration
WO2008096779A1 (ja) * 2007-02-09 2008-08-14 National University Corporation NARA Institute of Science and Technology Ｃ７０含有リポソームおよびその製造方法、並びにその利用
US8357401B2 (en) * 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
EP3572071A1 (en) 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
CA2853685C (en) 2011-11-04 2019-09-03 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
NZ630219A (en) 2012-03-28 2016-09-30 Discovery Lab Inc Lyophilization of synthetic liposomal pulmonary surfactant
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
SI2858974T1 (sl) 2012-06-08 2019-01-31 Nitto Denko Corporation Lipidi za formulacije za dostavo terapevtskega sredstva
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
SMT202100196T1 (it) * 2015-07-22 2021-05-07 Nitto Denko Corp Composizioni e metodi per forme liofile di nanoparticelle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN103748078A (zh) * 2011-06-08 2014-04-23 夏尔人类遗传性治疗公司 可裂解脂质

Also Published As

Publication number Publication date
US20240000710A1 (en) 2024-01-04
JP6875373B2 (ja) 2021-05-26
JP7268079B2 (ja) 2023-05-02
CA2992849A1 (en) 2017-01-26
EP3324932A1 (en) 2018-05-30
DK3324932T3 (da) 2021-04-06
CA2992849C (en) 2023-06-13
IL257029B (en) 2021-12-01
MX2018000891A (es) 2018-06-11
JP2018521083A (ja) 2018-08-02
IL257029A (en) 2018-03-29
PT3324932T (pt) 2021-04-06
EA201890367A1 (ru) 2018-06-29
US11737982B2 (en) 2023-08-29
IL288342A (en) 2022-01-01
SI3324932T1 (sl) 2021-07-30
CN113679689A (zh) 2021-11-23
US20190231695A1 (en) 2019-08-01
CN108024957A (zh) 2018-05-11
WO2017015552A1 (en) 2017-01-26
MX373982B (es) 2020-07-15
RS61607B1 (sr) 2021-04-29
PL3324932T3 (pl) 2021-07-05
CN113679689B (zh) 2023-09-01
US10300018B2 (en) 2019-05-28
HUE053990T2 (hu) 2021-08-30
ES2862191T3 (es) 2021-10-07
CY1123984T1 (el) 2022-05-27
HRP20210523T1 (hr) 2021-05-14
US20170020819A1 (en) 2017-01-26
TW201717914A (zh) 2017-06-01
EP3324932B1 (en) 2021-03-10
US12311055B2 (en) 2025-05-27
AU2016297153B2 (en) 2021-02-25
SMT202100196T1 (it) 2021-05-07
KR102716928B1 (ko) 2024-10-11
CN108024957B (zh) 2021-08-24
IL288342B1 (en) 2023-10-01
KR20180030698A (ko) 2018-03-23
EP3324932A4 (en) 2019-03-06
EA035761B1 (ru) 2020-08-06
BR112018001178A2 (pt) 2018-09-11
LT3324932T (lt) 2021-04-26
JP2021119161A (ja) 2021-08-12
IL288342B2 (en) 2024-02-01
AU2016297153A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
TWI355946B (en) Proliposomal and liposomal compositions of poorly
Kumar et al. Advances in self-assembled injectable hydrogels for cancer therapy
JP5923177B2 (ja) 新規な遺伝子伝達用組成物
Tariq et al. Nanogel-based transdermal drug delivery system: a therapeutic strategy with under discussed potential
CN109771663B (zh) 一种酸响应性抗癌纳米药物的制备及应用
Abdelaziz et al. Solid lipid nanoparticle-based drug delivery for lung cancer
KR20110056042A (ko) 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
JP6230538B2 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
Upadhyay et al. Vesicular approach review on nanocarriers bearing curcumin and applications
Ghosal et al. Multi-vesicular liposome and its applications: a novel chemically modified approach for drug delivery application
JP2023168587A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
WO2005021012A1 (ja) ゲムシタビン封入薬剤担体
CN104840432A (zh) 一种紫杉烷类长循环纳米粒及其制备方法
Qiu et al. Progress in nasal drug delivery research based on biomaterials
BR112018001178B1 (pt) Composição, processo de produção de liófilo sólido, liófilo sólido, processo de preparação de um medicamento, medicamento e processo de preparação de um medicamento de ácido nucleico
Parida et al. Lipid-Based Nanocarriers: Panacea for Improving Oral Bioavailability of Lipophilic Drugs
JPWO2017110772A1 (ja) リポソーム及びリポソーム組成物